Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Maqola

Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers

Sylvain JulienAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaAleksandar ÍveticAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaAnita GrigoriadisAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaDing QiZeAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaBrian BurfordAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaDaisy SprovieroAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaGianfranco PiccoAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaCheryl GillettAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaSuzanne L. PappAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaLana SchafferAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaAndrew TuttAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaJoyce Taylor‐PapadimitriouAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaSarah E. PinderConsortium for Functional Glycomics, The Scripps Research Institute, La Jolla, CaliforniaJoy BurchellAuthors' Affiliations: 1Breast Cancer Biology, King's College London, Guy's Hospital; 2Membrane/Cytoskeleton Signalling Group, Cardiovascular Division, James Black Centre, King's College London; 3Breakthrough Breast Cancer Research Unit, King's College London, Guy's Hospital; 4Breast Research Pathology, Research Oncology, King's College London, Guy's Hospital, London, United Kingdom; and 5Consortium for Functional Glycomics, The Scripps Research Institute, La Jolla, California
2011en
ABI

Annotatsiya

The glycome acts as an essential interface between cells and the surrounding microenvironment. However, changes in glycosylation occur in nearly all breast cancers, which can alter this interaction. Here, we report that profiles of glycosylation vary between ER-positive and ER-negative breast cancers. We found that genes involved in the synthesis of sialyl-Lewis x (sLe(x); FUT3, FUT4, and ST3GAL6) are significantly increased in estrogen receptor alpha-negative (ER-negative) tumors compared with ER-positive ones. SLe(x) expression had no influence on the survival of patients whether they had ER-negative or ER-positive tumors. However, high expression of sLe(x) in ER-positive tumors was correlated with metastasis to the bone where sLe(x) receptor E-selectin is constitutively expressed. The ER-positive ZR-75-1 and the ER-negative BT20 cell lines both express sLe(x) but only ZR-75-1 cells could adhere to activated endothelial cells under dynamic flow conditions in a sLe(x) and E-selectin-dependent manner. Moreover, L/P-selectins bound strongly to ER-negative MDA-MB-231 and BT-20 cell lines in a heparan sulfate (HS)-dependent manner that was independent of sLe(x) expression. Expression of glycosylation genes involved in heparan biosynthesis (EXT1 and HS3ST1) was increased in ER-negative tumors. Taken together, our results suggest that the context of sLe(x) expression is important in determining its functional significance and that selectins may promote metastasis in breast cancer through protein-associated sLe(x) and HS glycosaminoglycans.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba